Mylan Acknowledges Exercise of Full Call Option by the Independent Foundation
Mylan N.V. today acknowledged the exercise of the full call option by Stichting Preferred Shares Mylan, an independent foundation ("stichting") incorporated under the laws of the Netherlands.
PRESS RELEASE
HERTFORDSHIRE, England
and
PITTSBURGH
,
July 23, 2015
/
/ -- Mylan N.V. (NASDAQ: MYL) today acknowledged the exercise of the
full
call option by Stichting Preferred Shares Mylan, an independent foundation ("
stichting
") incorporated under the laws of
the Netherlands
(the "Foundation"). The Foundation notified Mylan that it has exercised its call option to acquire 488,388,431 Mylan preferred shares pursuant to the Call Option Agreement, dated
April 3, 2015
, between Mylan and the Foundation.
ABOUT MYLAN
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which nearly 50% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. Our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com.
